GU Cancers 2023 | Clinical trials in kidney cancer to look out for

Michael Atkins, MD, Lombardi Comprehensive Cancer Center, Washington DC, highlights soon-to-be-published trials with key results in advanced clear cell renal carcinoma (ccRCC) therapy. The CA209-8Y8 study (NCT03873402) comparing nivolumab and ipilimumab in poor risk patients is discussed, as well as research into nivolumab, adjuvant therapy, and combination trials such as the CheckMate 914 study (NCT03138512). Dr Atkins also shares insight into his own hopes from future trials, focusing on an immunotherapeutic front-line approach and appropriate landmark endpoints. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.